RAD51 Inhibitors/Activators

RAD51 Products

All (7)
RAD51 Inhibitors (5)
RAD51 Activator (1)
New RAD51 Products

Cat.No.	Product Name	Information	Product Use Citations
S2871	T0070907	T0070907 is a potent inhibitor of PPARγ (peroxisome proliferator activator receptor γ ) that induces G2/M arrest and enhances the effect of radiation in human cervical cancer cells through mitotic catastrophe. It also acts as an antagonist of PPARγ that suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms.	Cell Rep Med, 2025, 6(10):102373 Front Pharmacol, 2025, 16:1559446 Sci Rep, 2025, 15(1):17232
S1244	Amuvatinib (MP-470)	Amuvatinib (MP-470, HPK 56) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively. Amuvatinib suppresses c-MET and c-RET. Amuvatinib is also active as a DNA repair protein Rad51 inhibitor with antineoplastic activity. Phase 2.	Cancer Res, 2025, 10.1158/0008-5472.CAN-24-2220 Hematol Oncol, 2025, 43(5):e70131 bioRxiv, 2024, 2023.11.21.568071
S8077	RI-1	RI-1 (RAD51 inhibitor 1) is a RAD51 inhibitor with IC50 ranging from 5 to 30 μM.	Cell Rep Med, 2025, 6(8):102284 MedComm (2020), 2024, 5(8):e690 Cell Death Discov, 2024, 10(1):434
S8234	RS-1	RS-1 is a RAD51-stimulatory compound, which increases the DNA binding activity of RAD51. It is an HDR(homology-directed repair) enhancer that enhances Cas9- and TALEN-mediated knock-in efficiency in rabbit embryos both in vitro and in vivo.	Sci Bull (Beijing), 2025, S2095-9273(25)00865-5 Funct Integr Genomics, 2025, 25(1):180 J Biomed Sci, 2024, 31(1):68
F1110	Rad51 Antibody [H22D22]	Rad51
E0308^New	RAD51-IN-17	RAD51-IN-1, a B02 derivative, functions as a potent RAD51 inhibitor. This compound is applicable for cancer research investigations.
S9941^New	Emzadirib	Emzadirib, an inhibitor of RAD51, exhibits a reduction in RAD51 foci. This compound displays significant anti-tumor activity with tumor growth inhibition in in vivo and in vitro models.
S2871	T0070907	T0070907 is a potent inhibitor of PPARγ (peroxisome proliferator activator receptor γ ) that induces G2/M arrest and enhances the effect of radiation in human cervical cancer cells through mitotic catastrophe. It also acts as an antagonist of PPARγ that suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms.	Cell Rep Med, 2025, 6(10):102373 Front Pharmacol, 2025, 16:1559446 Sci Rep, 2025, 15(1):17232
S1244	Amuvatinib (MP-470)	Amuvatinib (MP-470, HPK 56) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively. Amuvatinib suppresses c-MET and c-RET. Amuvatinib is also active as a DNA repair protein Rad51 inhibitor with antineoplastic activity. Phase 2.	Cancer Res, 2025, 10.1158/0008-5472.CAN-24-2220 Hematol Oncol, 2025, 43(5):e70131 bioRxiv, 2024, 2023.11.21.568071
S8077	RI-1	RI-1 (RAD51 inhibitor 1) is a RAD51 inhibitor with IC50 ranging from 5 to 30 μM.	Cell Rep Med, 2025, 6(8):102284 MedComm (2020), 2024, 5(8):e690 Cell Death Discov, 2024, 10(1):434
E0308^New	RAD51-IN-17	RAD51-IN-1, a B02 derivative, functions as a potent RAD51 inhibitor. This compound is applicable for cancer research investigations.
S9941^New	Emzadirib	Emzadirib, an inhibitor of RAD51, exhibits a reduction in RAD51 foci. This compound displays significant anti-tumor activity with tumor growth inhibition in in vivo and in vitro models.
S8234	RS-1	RS-1 is a RAD51-stimulatory compound, which increases the DNA binding activity of RAD51. It is an HDR(homology-directed repair) enhancer that enhances Cas9- and TALEN-mediated knock-in efficiency in rabbit embryos both in vitro and in vivo.	Sci Bull (Beijing), 2025, S2095-9273(25)00865-5 Funct Integr Genomics, 2025, 25(1):180 J Biomed Sci, 2024, 31(1):68
E0308^New	RAD51-IN-17	RAD51-IN-1, a B02 derivative, functions as a potent RAD51 inhibitor. This compound is applicable for cancer research investigations.
S9941^New	Emzadirib	Emzadirib, an inhibitor of RAD51, exhibits a reduction in RAD51 foci. This compound displays significant anti-tumor activity with tumor growth inhibition in in vivo and in vitro models.